Statin Use Linked to Reduced Risk of High-Grade Prostate Cancer

Strategic Insights -

Research conducted in Montpellier, France has found an inverse association between high-grade prostate cancer and statins, particularly lipophilic statins. A French population-based case-control study, known as the EPICAP study, included 819 incident prostate cancer cases and 879 population-based controls. The study found that the use of overall antilipemic drugs was not associated with prostate cancer risk, while the use of statins, and particularly lipophilic statins was inversely associated with high-grade prostate cancer.

Key Takeaways:

  • The EPICAP study, a French population-based case-control study, found an inverse association between high-grade prostate cancer and statins, particularly lipophilic statins.
  • Long duration (10 years) of statin and lipophilic statin use was inversely associated with prostate cancer overall and high-grade prostate cancer.
  • The study concluded that high-grade prostate cancer was inversely associated with statins, particularly lipophilic statins, and that these associations were more pronounced for long duration.
  • The research suggested that these associations could help improve targeted screening strategies.
  • Pierre-Jean Lamy and Co-Researchers conducted the study, which was published in Cancer Epidemiology Biomarkers & Prevention in 2025.
  • The study included detailed information on the use of antilipemic drugs, which was collected as part of the EPICAP study.

Statistics:

  • The EPICAP study included 819 incident prostate cancer cases and 879 population-based controls.
  • The study found that the use of lipophilic statins was inversely associated with high-grade prostate cancer (OR=0.52, 95%CI 0.27-1.00).
  • Long duration (10 years) of lipophilic statin use was inversely associated with high-grade prostate cancer (OR=0.269, 95% CI 0.09-0.72).

Sources:

  • Pierre-Jean Lamy et al. (2025). Statin and other antilipemic use and prostate cancer : Results from the EPICAP study. Cancer Epidemiology Biomarkers & Prevention, 2025.
  • NewsRx. Studies from Pierre-Jean Lamy and Co-Researchers Update Current Data on Prostate Cancer (Statin and other antilipemic use and prostate cancer : Results from the EPICAP study). Health & Medicine Week, 2025; p 7341.
  • Cancer Epidemiology Biomarkers & Prevention. Publisher contact information: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA.